Safety and dose modification for patients receiving niraparib
Jonathan S. Berek(Stanford University), Ursula A. Matulonis(Dana-Farber Cancer Institute), Ulla Peen(Herlev Hospital), Prafull Ghatage(University of Calgary), Sven Mahner(Ludwig-Maximilians-Universität München), Andrés Redondo(Spanish Ovarian Cancer Research Group), Anne Lesoin, Nicoletta Colombo(European Institute of Oncology), Ignace Vergote(KU Leuven), Ora Rosengarten(Shaare Zedek Medical Center), Jonathan A. Ledermann(University College London), Mario Javier Pineda, Susan Ellard(University of British Columbia), Jalid Sehouli(Charité - Universitätsmedizin Berlin), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Dominique Berton-Rigaud(Institut de Cancérologie de l'Ouest), Radosław Mądry(Poznan University of Medical Sciences), Alexander Reinthaller(Comprehensive Cancer Center Vienna), Sebastien Hazard(Tesaro (United States)), Wenwen Guo(Tesaro (United States)), Mansoor R. Mirza(Rigshospitalet)
Cited by 186